Johnson and Johnson – The track records of Amgen and Johnson & Johnson so far in 2016 have been quite different
httpss://www.youtube.com/watch?v=Ef129P268X0 The track records of Amgen and Johnson & Johnson so far in 2016 have been quite different. Amgen expects much more growth from Kyprolis, in particular. Amgen should announce results from a major cardiovascular outcomes study in the first quarter of 2017 that might convince payers to loosen their purse strings. Then t’s the...